Wei Liu

Radiation oncologist at BC Cancer

[C. Jillian Tsai, MD, PhD @CJTsaiMDPhD]

1)🚨Just out @TheLancet - CURB randomized phase 2 RCT of SBRT for oligoprogressive metastatic NSCLC and breast cancer.
https://t.co/Yc8n2Gyy7P

@simonpowell213 @MSK_RadOnc @MSKCancerCenter @MSKBiostats @RadMedPM @UofTDRO @thePMCF @pmcancercentre @JYangMDPhD @ipreeshagul @PamelaDrullins1 @ErinGillespieMD @imrtlee @xrtGenomics @charlesrudin @DanHigginsonMD @AmyXuMDPhD @theRADSofKHAN @DKirschMDPhD @ldawsonmd

[Sympascho Young MD @DrSymYoung]

@drviviantan presenting 5-year clinical outcomes for patients with solitary vs bilateral kidneys treated with SBRT at #ASTRO2023. SBRT safe and effective for RCC, even with solitary kidneys. 👏👏Compelling study!! @DrCorreaRO @_ShankarSiva @DrAlexLouie

[Sympascho Young MD @DrSymYoung]

Exciting RCT presented at #ASTRO2023 by @Melissa_O_Neil on use of diagnostic CT in lieu of CT sim for palliative patients, improving workflow and saving time/resources 👏👏 Great work!! @drdavidpalma @TimkWin @goodmanC_MD @Drjoannalaba

[Vivian Tan MD @drviviantan]

Published “Top 10 Lessons Learned from Trials in Oligometastatic Cancers” in CRT reviewing #SABR outcomes, toxicity, costs, combination with systemic therapies and barriers to accrual for trials
@drdavidpalma #radonc #onctwitter #medtwitter
https://t.co/RK8pBBRPZ4

[Scott Tyldesley @tyldesley_scott]

An Updated Analysis of the Survival Endpoints of ASCENDE-RT - out in Red Journal https://t.co/QGl7mLm70q

[Melissa O'Neil, MSc, MRT(T) @Melissa_O_Neil]

Hot off the digital presses...the DART RCT protocol is now published in BMC Palliative Care https://t.co/VDyq3GM0c6
We also just passed 50% accrual and look forward to adding randomized evidence to the growing body of work in "sim-free" palliative RT
#palliativecare #simfree

[Robert Anton Olson @DrOlsonOncology]

Should Stereotactic Ablative Radiotherapy Be Used for Oligometastatic Disease? | NEJM Evidence https://t.co/pUFx17U46J

[Journal of Clinical Oncology @JCO_ASCO]

🔥 Check out what’s hot this week in #JCO:

Oligometastases: Emerging Evidence ➡️ https://t.co/7KbHN6vJP4 #radonc @drdavidpalma

[Wei Liu @WeiLiuRO]

@changjeesuk1 Thanks Jee Suk! Agree that these can be important barriers.

[Wei Liu @WeiLiuRO]

Happy to share our thoughts in the JCO on the randomized evidence on oligometastases, challenges in producing randomized evidence in this space, and ongoing phase III trials. @drdavidpalma @HoudaBahig
https://t.co/s85bZTEMB7

[Wei Liu @WeiLiuRO]

Many phase III trials are ongoing and will help to define the oligometastatic state, identify biomarkers, and confirm the benefits observed in phase II studies.

[Wei Liu @WeiLiuRO]

Barriers such as off-trial availability and clinicians' lack of equipoise have made completion of randomized trials challenging, and we propose strategies to overcome these barriers.

[JeeSuk Chang @changjeesuk1]

Final version of manuscript is now available online @IJROBP
Again, the OMD state could represent a continuous spectrum of disease burden.
My top conundrum.. Dose 1-3 definition come from the fact that we can treat <= 3 or 5 lesions easily and safely?

https://t.co/Z3UzEe4WTq

[Robert Anton Olson @DrOlsonOncology]

Proud of my team in BC for completing the SABR-5 trial, which demonstrates SABR is safe in patients treated for oligometastases, in a well coordinated, peer-reviewed population-based program. https://t.co/EfZdLMMP79

[Jason Beckta @drbeckta]

2022: cancer staging? There's an app for that. Memorizing AJCC manuals harkens from a time of phone booths and Blockbuster. Except for RadOnc! Since I don't believe in brute-force techniques, I created a "Mind Map" for mentally consuming the AJCC 8th edition:

[Alex Louie MD, PhD @DrAlexLouie]

Radiation☢️is an effective treatment to reduce symptoms from advanced lung cancer - can modern RT reduce treatment-related side effects? - a🧵on the🇨🇦phase III PROACTIVE RCT... #radonc #lcsm https://t.co/X4IiQ5OqqO

[Rohann Correa @DrCorreaRO]

Such a pleasure to work with mentor @DrAndrewLoblaw & the GU 'Dream Team' @Sunnybrook on this project! 🙏🏽🙏🏽🙏🏽

[Lorenzo Madrazo @LorenzoMadrazo]

As one of the senior residents in the ED admitting patients to the hospital over the last few weeks, there's nothing "mild" about how #COVID19 continues to affect the most vulnerable (elderly, comorbid, immunocompromised).

🧵1/4